CDMO Services for Cells

CAR-T cells, i.e. the Chimeric Antigen Receptor T Cell, work in the principle of utilizing the patient's own T lymphocytes, which are re-engineered in the lab, loaded with receptors recognizing the tumor-antigen, proliferated ex vivo, and subsequently re-infused to the patient, to recognize and attack the tumor cells. Hillgene is specialized in provision of integrated CDMO solutions for cellular therapy products, has established a completely closed process development platform for cellular therapy products, and therefore, can provide high-quality CDMO services for cells to clients with various demands.

CAR-T cells, i.e. the Chimeric Antigen Receptor T Cell, work in the principle of utilizing the patient's own T lymphocytes, which are re-engineered in the lab, loaded with receptors recognizing the tumor-antigen, proliferated ex vivo, and subsequently re-infused to the patient, to recognize and attack the tumor cells. Hillgene is specialized in provision of integrated CDMO solutions for cellular therapy products, has established a completely closed process development platform for cellular therapy products, and therefore, can provide high-quality CDMO services for cells to clients with various demands.

CAR-T cells, i.e. the Chimeric Antigen Receptor T Cell, work in the principle of utilizing the patient's own T lymphocytes, which are re-engineered in the lab, loaded with receptors recognizing the tumor-antigen, proliferated ex vivo, and subsequently re-infused to the patient, to recognize and attack the tumor cells. Hillgene is specialized in provision of integrated CDMO solutions for cellular therapy products, has established a completely closed process development platform for cellular therapy products, and therefore, can provide high-quality CDMO services for cells to clients with various demands.

CAR-T cells, i.e. the Chimeric Antigen Receptor T Cell, work in the principle of utilizing the patient's own T lymphocytes, which are re-engineered in the lab, loaded with receptors recognizing the tumor-antigen, proliferated ex vivo, and subsequently re-infused to the patient, to recognize and attack the tumor cells. Hillgene is specialized in provision of integrated CDMO solutions for cellular therapy products, has established a completely closed process development platform for cellular therapy products, and therefore, can provide high-quality CDMO services for cells to clients with various demands.